Peer-Reviewed Publication
Future Oncol2026;22(11):1331-1340.May 1, 2026Journal Article
Real-world treatment patterns and outcomes of patients with multiple myeloma initiating elranatamab: results from the ALTITUDE-1 and ALTITUDE-2 retrospective cohort studies.
Rahul Banerjee1, Meera Mohan2, Bhavesh Shah3, Patricia Prince4, Nileesa Gautam4, Elisha Beebe4, William Pajerowski5, Cera Cantu5, Hannah Meiseles5, David Hughes6, Guido Nador7, Rickard Sandin8, Patrick Hlavacek9, Benjamin Li9, Aster Meche9, Chai Hyun Kim9, Isabel Perez Cruz9, Mohsena Sumaya9, Marco DiBonaventura9
1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
2Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
3Hematology Oncology Pharmacy, Boston Medical Center, Boston, MA, USA.
4Science, Aetion, New York, NY, USA.
5Clarify Insights, Clarify Health, San Francisco, CA, USA.
6Oncology Medical Affairs, Pfizer Inc, Cambridge, MA, USA.
7Oncology Medical Affairs, Pfizer Ltd, Surrey, UK.
8Global Access & Value, Pfizer AB, Stockholm, Sweden.
9Global Access & Value, Pfizer Inc, New York, NY, USA.
Abstract
BACKGROUND AND AIM: Elranatamab is a bispecific antibody currently approved in the United States (US) for the treatment of relapsed/refractory multiple myeloma (MM). Given its recent approval, real-world data are limited.
METHODS: Results from two real-world (RW) studies using administrative claims (ALTITUDE-1) and fee-for-service data (ALTITUDE-2) are collectively reported here. US patients with…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans